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1. Introduction 
Coronary artery disease (CAD) and its one of the severe clinical manifestation, Acute 
Myocardial Infarction (AMI) continue to be significant cause of morbidity and mortality in 
both men and women around the world. The extent of myocardial damage after an acute 
coronary event of atherothrombosis determines the prognosis. The diagnosis of acute coronary 
syndrome (ACS) encompassing unstable angina, non ST elevated myocardial infarction 
(NSTEMI) (Bertrand et al., 2002; Braunwald et al., 2000; Hamm et al., 2001) to STEMI (AMI) 
(Alpert et al., 2000), is based on a combination of symptoms, electrocardiographic changes and 
biomarkers. 
The physical examination can be inadequate in identifying atypical chest pain from chest 
pain of cardiac origin. On one hand 33% of patients with ACS have no chest pain. On the 
other hand approximately half of patients with acute chest pain, who have the initial 
diagnostic findings of ACS and are admitted to the hospital, are later found not to suffer 
from ACS. In the majority of patients with chest pain, the electrocardiogram (ECG) is the 
most readily available tool for identifying patients with ACS. However, the ECG is also 
often not diagnostic for acute chest pain and in fact; the sensitivity of borderline ECG for 
detecting ACS is only 60% (Canto et al., 2000, Panteghini, 2002).  
Over the last 50 years, the contribution of laboratory Medicine to the management of cardiac 
diseases has become increasingly sophisticated. In 1950s, Karmen et al first reported that 
enzyme released from necrotic cardiac myocytes could be detected in the serum and could 
be used in the diagnosis of MI. The ensuing years witnessed progressive improvement in 
the type of cardiac tissue specific biochemical markers and a corresponding enhancement in 
the clinical sensitivity and specificity of their use.  
1.1 Current practice of diagnostic biomarkers in ACS 
Today, markers of myocardial necrosis at the down stream of the pathophysiology of ACS; some 
specific to myocardial necrosis have gained their mark under routine diagnosis of ACS (Table 1).  
1.1.1 Myoglobin 
The main advantage of myoglobin is early detection of patients with AMI (Gibler et al., 1987, 
Roxin et al., 1984). The NACB Laboratory Medicine Practice Guidelines have recommended 
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myoglobin in addition to cardiac troponins (cTn) for the diagnosis of AMI patients who 
present within the 6 hours of onset of symptoms (Apple et al., 2007). The serum myoglobin 
level rises faster than Creatinine Kinase-MB (CK-MB) and cTn, reaching twice the normal 
values within 2 hours and peaking within 4 hours of symptom onset. The disadvantage of 
using myoglobin alone is that it has poor specificity for AMI in patients with concurrent 
trauma or renal failure. 
 
Current Biomarkers 
Myoglobin 
Creatine Kinase-MB 
Troponins 
Natriuretic Peptides 
Table 1. Current Biomarkers 
1.1.2 Creatinine Kinase (CK) 
CK-MB, the specific cardiac isoform of CK can be used in the diagnosis of myocardial 
necrosis (Mair et al., 1991). This was proposed by World Health Organization and was later 
extended for monitoring trends in cardiac disease (Apple et al., 2007, 2003). Elevation of CK-
MB occurs 4 to 6 hours after the onset of acute MI and remains for 24 to 48 hours. CK-MB is 
relatively sensitive but less specific as it can be elevated in any conditions following acute 
muscle injury or in patients undergoing any surgical procedure. Furthermore CK is present 
in skeletal muscle, intestine, diaphragm, uterus and prostate and thus the specificity of CK-
MB is impaired in the setting of injury to these organs. Moreover, serial analysis of CK-MB 
are required for quantitation as well as qualitative assessment of injury to cardiac muscle, 
therefore, many studies have suggested that a single cTn can be used as a convenient, cost 
effective and non invasive method for the diagnosis of myocardial necrosis (Apple et al., 
1999, De Winter et al., 1995). 
1.1.3 Cardiac troponin (cTn)s 
Undisputedly troponin (cTnI and cTnT) are the most sensitive and specific biomarker of 
myocardial injury (Bleier et al., 1998). The kinetics of both the troponins are detectable in the 
serum within 4 to 12 hours after the onset of acute MI and depending upon the duration of 
ischemia and reperfusion status, peak values occur 12 to 48 hours from symptom onset 
(Apple et al., 1999). The tissue specificity and reliable detected concentration of cTn in the 
peripheral circulation makes it a good indicative of myocardial injury (Bleier et al., 1998). 
Moreover, several studies have shown that patients presenting with elevated cTns had a 
poor prognosis compared to those without detectable cTns (Panteghini, 2002). Because both 
forms of cTn remain in the circulation several days after injury, it allows for diagnosis  even 
in patients who present very late (Apple et al., 2003). However because of long half lives, 
one of the disadvantages using the cTn is that neither cTnI nor cTnT can be used for 
detection of reinfarction after an index event. The other disadvantage of cTnT is that it is 
present in small amounts in skeletal muscle and is re -expressed in diseases that involve 
skeletal muscle degeneration. Therefore, an elevated cTn without clinical evidence of ACS 
should prompt for other possible myocardial injuries, including cardiac trauma, cardiac 
failure, and hypertension (Panteghini, 2002). 
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1.1.4 Natriuretic peptides 
B –Natriuretic peptide (BNP) and its prohormone N-terminal pro BNP (Nt-proBNP) are 
neurohormones secreted from cardiac ventricles in response to ventricular wall stress (de 
Bold, 1985, Nakako et al., 1992). BNP, an established biomarker for patients with heart 
failure, and NT-pro BNP are elevated in ACS and can identify patients at very high risk for 
adverse cardiovascular events including death (de Lemos &Marrow, 2002, Ishibashi, 2002). 
The utility of BNP and NT-pro BNP as markers is based on the finding that it increases in 
the left ventricle during remodeling after a transmural infarction or as a consequence of 
previous ischemic damage (Lorgis et al., 2007). However these peptides have poor 
specificity for the diagnosis of ACS since elevated levels can also be seen in patients with 
renal failure, primary aldosteronism, congestive heart failure and thyroid disease. 
Despite the success of these biomarkers, there is still a need for the development of early 
markers that can reliably rule out ACS in the emergency room at presentation and also 
detect myocardial ischemia in the absence of reversible myocyte injury. Misdiagnosis  
has been reported to be the main cause of treatment delays. Undetected infarctions remain a 
serious public health issue and represent the leading cause of malpractice cases in  
the emergency settings. These imperfect strategies resulting in costly and inappropriate 
management decisions have forced us to search new non-invasive quick strategies  
in identifying the high-risk individuals. One of them is identifying novel cardiac 
biomarkers.  
Biomarkers have multiple uses in the arenas of research and practice. It is defined as a 
characteristic that is objectively measured and evaluated as an indicator of normal biological 
processes, pathogenic processes, or pharmacologic responses to a therapeutic interventions. 
In clinical practice, a biomarker may be used to diagnose a medical problem, serve as a tool 
for staging disease, or provide an indicator of differential prognosis. 
1.2 In search for novel cardiac biomarkers of ACS 
Recent investigations have been directed towards analyzing components, involved in the 
pathogenesis of ACS, at upstream from biomarkers of necrosis, such as components released 
during Ischemia, components of plaque destabilization and rupture, factors of thrombosis, 
components representing oxidative stress, molecules of inflammation and acute phase 
reactants for earlier assessment of overall patient risk of adverse event and indexing them 
under “Biomarkers” (Table 2). 
1.2.1 Components released during ischemia 
The explicit goal is to maintain micro-circulatory flow to prevent even minor infarctions. 
Only marker that precedes necrosis and permits prevention of the consequence can meet the 
clinical need. Identifying markers of ischemia even if necrosis is not present may help in 
identifying a high risk individual who may in very near future experience the consequences 
of the infarct. The components that have been studied in this group are Free Fatty Acids 
unbound to Albumin (FFAu), Choline, Ischemia-Modified albumin (IMA) and Heart type 
Fatty Acid Binding Protein (H-FABP).  
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Components Released during Ischemia 
Free Fatty Acids unbound to Albumin (FFAu) 
Ischemia Modified Albumin (IMA) 
Choline 
Heart type Fatty acid binding protein (H-FABP) 
Thrombotic Factors
Soluble CD40 Ligand (sCD40L) 
P-selectin 
Tissue Factor (TF) 
Plasminogen Activator Inhibitor-1 (PAI-1) 
Components involved in Plaque Rupture
Myeloperoxidase (MPO) 
Metalloproteinases (MMPs) 
Cathepsins 
Pregnancy-associated plasma protein-A (PAPP-A) 
Components representing oxidative stress 
Oxidized LDL (Ox-LDL) 
Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) 
Lipoprotein-associated phospholipase A-2 (Lp-PLA-2) 
Molecules of Inflammation
Vascular Cell Adhesion Molecule (VCAM-1), 
Platelet Endothelial Cell Adhesion Molecule (PECAM-1) 
Cystatin C 
High-sensitivity C - reactive protein (HsCRP) 
Table 2. Emerging Biomarkers 
1.2.1.1 Free Fatty Acids unbound to albumin (FFAu) 
Increased blood catecholamines in association with ischemia can cause increased FFA by 
activating lipid hydrolysis within the heart and adipose tissue. Apart from this, reduction of 
FFA use after ischemia can also cause increased serum concentration of FFA. The observed 
increase in free fatty acids unbound to albumin (FFAu) in the blood with acute myocardial 
ischaemia has been evaluated for the early identification of cardiac injury (Kleinfeld et al., 
1996). Two groups of investigators have preliminarily studied the sensitivity of this marker 
at patient presentation to the emergency room and have shown that FFAu was elevated well 
before other, more traditional, markers of cardiac necrosis and had at admission sensitivity 
of >90% (Kleifeld et al., 2002, Adams et al., 2002). 
1.2.1.2 Ischemia Modified Albumin (IMA) 
Due to ischemia the metal binding site on the amino terminus of albumin is damaged. The 
albumin of patient with myocardial ischemia exhibit lower metal binding capacity for cobalt 
than that of normal patients (Bar-Or et al., 2001a). IMA gained its importance as it 
demonstrated a good “negative predictive value.” In the assay, Cobalt less bound to 
albumin reacts with the indicator (Bar-Or et al., 2000). Significant changes in albumin cobalt 
binding were documented to occur minutes after transient ischemia induced by balloon 
angioplasty and to return to baseline within 12 hours (Bar-Or et al., 2001b). However its 
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presence during ischemia of any other organ and in individual with inherent reduced cobalt 
binding giving false positive results, lost its specificity for routine use in detection of 
ischemia (Collinson & Gaze, 2008). However correlating with the clinical conditions and 
other markers may find its use in identifying high risk individuals. 
1.2.1.3 Choline 
Choline is a biomarker that is released when phospholipids are cleaved, which suggests that 
perhaps it could be a marker of ischemia and/or necrosis (Danne & Möckel, 2010). 
Experimental studies have demonstrated that phospholipase D enzyme activation and 
release of choline in blood are related to major processes of myocardial ischemia. Several 
studies suggested that the marker might improve prognostication in patients with ACS 
(Danne et al., 2003). In a study with troponin negative patients, choline detected high-risk 
unstable angina with a sensitivity and specificity of 86%. Additional studies are however 
needed to fully investigate the clinical significance of this marker (Apple et al., 2005).  
1.2.1.4 Heart type Fatty Acid Binding Protein (H-FABP) 
H-FABP is a low molecular weight protein involved in myocardial fatty-acid metabolism 
(Glatz et al., 1997). This protein is rapidly released immediately after infarction. H-FABP has 
been shown in mouse studies to be an early marker of ischaemia (Glatz et al., 1988) (before 
morphological evidence of myocardial necrosis) and can therefore help with diagnosis of MI 
earlier (Glatz et al., 1988, C. P. Chen et al., 2004, L. Chen et al., 2004). However, studies 
attempting to use H-FABP alone for early diagnosis of AMI have produced disappointing 
results. One review of six studies found that the pooled positive predictive value to be 65.8% 
and pooled negative predictive value to be 82.0% (Body, 2009). Also it still lacks cardiac 
specificity as it is found in brain, kidney and skeletal tissue and levels can go up in acute 
ischaemic strokes and intense exercise. Thus its role as biomarker needs further evaluation.  
In a recent study, Bhardwaj et al (2011) evaluated an array of established and emerging 
cardiac biomarkers for ACS among patients with chest discomfort in the emergency 
department. In their study neither IMA nor H-FABP detected or excluded ACS. Among 
patients with symptoms suggestive of ACS, results for NT-proBNP, hsTnI or FFA added 
diagnostic information to cTnT. In the context of hsTnI results, FFA measurement 
significantly reclassified both false negatives and false positives.  
1.2.2 Thrombotic factors 
Plaque disruption and thrombus formation in coronary arteries lead to a variable degree of 
luminal obstruction to the blood flow and can present clinically as unstable angina or AMI 
and lead to a sudden death. Three major determinants of thrombotic response are (a) the 
presence of local thrombogenic substances, (b) the local flow disturbances and, (c) the 
systemic thrombotic propensity. Thus apart from the local thrombogenic potential even 
systemic pro-coagulant status may determine the severity of the acute event of thrombosis. 
1.2.2.1 sCD40 ligand (sCD40L) 
The CD40 and CD40 ligand (CD40L) system is expressed on a variety of cell types including 
activated platelets, vascular endothelial cells, vascular smooth muscle cells, monocytes, and 
macrophages. CD40L is a trimeric, transmembrane protein (Hennet al., 2001). Following 
expression on the cell surface, CD40L is partly cleaved by proteases and subsequently 
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released into the circulation as sCD40L which can be detected in serum and plasma. The 
main source of circulating sCD40L is platelets (Hennet al., 2001). The binding of CD40L 
enhances the inflammatory response, acts prothrombotically, leads to plaque destabilization, 
and inhibits endothelial regeneration. From several clinical studies it has consistently been 
reported that sCD40L is elevated in patients with ACS and that it provides prognostic 
information with therapeutic implications independent of established cardiac markers, e.g. 
cardiac troponins (Heesechen et al., 2003). However, pre-analytical conditions are decisive for 
the assessment of sCD40L and may preclude routine clinical use (Weber et al., 2006). 
1.2.2.2 P-selectin 
P-selectin is a cell surface glycoprotein that plays a critical role in the migration of 
lymphocytes into tissues. It is found constitutively in a preformed state in the Weibel-Palade 
bodies of endothelial cells and in α-granules of platelets. This stored P-selectin is mobilized 
to the cell surface within minutes in response to a variety of inflammatory and 
thrombogenic agents. The mobilized P-selectin is apparently present on the cell surface for 
only a few minutes after which it is recycled to intracellular space. P-selectin also binds 
monocytes and neutrophils in addition to activated platelets and is responsible for 
incorporation of leukocytes into the growing thrombus (Malý et al., 2003). Thus, P-selectin is 
a marker of platelet activation which in turn is prerequisite for thrombosis (Serebruany et 
al., 1999a). Fijnheer et al (1997) have concluded that endothelial cell activation is associated 
with an increased P-selectin concentration per platelet. Elevated levels have been reported 
not only in AMI and unstable angina but also in stable angina. In our study significant 
negative correlation of sP-selectin with age in AMI group suggests increased pro-coagulant 
status in younger AMI patients (Mashru et al., 2010). Its role as biomarker requires extensive 
clinical evaluations. 
1.2.2.3 Tissue Factor (TF) 
TF at the upfront of the coagulation pathway plays a crucial role in initiating thrombus 
formation after plaque rupture in patients with ACS. Tissue injury disrupts vascular 
endothelium causing its release into circulating blood and hence activation of coagulation 
cascades. It activates extrinsic pathway of coagulation and act as cofactor for Factor VII 
(fVII) and initiates cell surface procoagulant activity. It is also known to activate factor X 
through intrinsic pathway by activating factor IX, leading to thrombin generation and fibrin 
formation. Since Suefuji et al in 1997 reported the role of TF in AMI, there have been many 
studies conducted to determine the status of plasma TF and AMI (Kamikura et al., 1997, 
Nishiyama et al., 1998, Malý et al., 2003, Morange et al., 2007, Xiong et al., 2007) with 
contradictory findings. We observed increased levels of TF in AMI at presentation (Shalia et 
al., 2010a). TF exposed from ruptured plaque is the actual trigger but systemic procoagulant 
status also plays important role. Independent of cellular TF, blood borne soluble TF may 
play a role in the propagation of thrombosis which also needs monitoring in early 
atherosclerotic conditions.  
1.2.2.4 Plasminogen Activator Inhibitor-1 (PAI-1) 
PAI-1 prevents fibrinolysis and thus accelerates thrombus formation. Immunohistochemical 
staining of coronary artery specimens (Shindo et al., 2001) and mRNA expression studies (F. 
Chen et al., 2005) have demonstrated increased expression of PAI. While the evidence of 
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increased PAI levels before first AMI attack, was given by Thogersen et al (1998). In our 
study, increased levels of PAI-1 were observed in AMI patients at presentation and were 
also more associated with younger AMI patients (Shalia et al., 2010). Hamstein et al (1985) 
have also reported elevated circulating concentrations of PAI-1 in young men at increased 
risk for recurrent infarction. 
1.2.3 Components involved in plaque rupture 
A growing understanding of the importance of atherosclerotic plaque rupture in the 
pathogenesis of coronary events has led to the identification of an expanding array of 
markers for plaque rupture. The enzymes that have gained importance in this aspect are 
myeloperoxidase, matrix metalloproteinases, cathepsins, etc.  
1.2.3.1 Myeloperoxidase (MPO) 
Leucocytes play a central role in atherosclerotic plaque rupture (de Servi et al., 1996). 
Myeloperoxidase is a degranulation product, secreted by a variety of inflammatory cells, 
including activated neutrophils, monocytes and macrophages such as those found in 
atherosclerotic plaques. It possesses proinflammatory properties and may contribute 
directly to tissue injury (Eiserich et al., 2002). Its systemic levels predicted future 
cardiovascular event independent of CD40L (Baldus et al., 2003) and gave in-vitro strong 
support to the role of neutrophil activation as an adjunct pathophysiological event in ACS 
that is directly different from platelet activation. Collectively the current evidence supports 
the need for further studies into the actual role of MPO. One of the important roles of 
Myeloperoxidase in leucocytes is to activate metalloproteinases that bring about plaque 
rupture (Zhang et al., 2001). 
1.2.3.2 Metalloproteinases (MMPs) 
The structural integrity of myocardial Extracellular Matrix (ECM) is dependent on 
endogenous zinc-dependent endopeptidases known as matrix metalloproteinases (MMP). 
These enzymes are regulated by tissue inhibitors of metalloproteinases (TIMPs) (Kelly et al., 
2008). MMPs may degrade myocardial ECM leading to the development of LV dilatation and 
heart failure and their inhibition in experimental models of AMI has been associated with 
reduced LV dilatation and wall stress. Elevated levels of MMP-9 and its major inhibitor TIMP1 
have been demonstrated to be associated with cardiovascular death, heart failure or both but 
not with re-infarction (Kelly et al., 2007). In our study we found that there was significant 
increase in circulating levels of MMP-9 as well as MMP-8 in AMI at presentation. Moreover 
the increase in MMP-8 was independent of High sensitive C-reactive protein (HsCRP) and 
MMP-9 (Shah et al., 2009). MMP-2 is also shown to be elevated post MI (Dhillon et al., 2009) 
and is associated with poor prognosis (Kelly et al., 2008a).  In another study we observed that 
Serum MMP-3 levels were significantly elevated at presentation of the acute MI as compared 
to controls (Shalia et al., 2010b) while Kelly et al (2008b) have demonstrated that MMP-3 peaks 
at 72 hours of MI and plateau levels are associated with increase in LV volume and a lower 
ejection fraction at follow up. Amongst various MMPs, it has been suggested that MMP-9 may 
be of value in evaluating patients after acute coronary events (Apple et al, 2005). 
1.2.3.3 Cathepsins 
Evidence has been obtained for expression in human atherosclerotic lesion of another matrix 
degrading enzymes cathepsin S, B, K, D and L (Jormsjö et al., 2002). Beside protease function 
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and vascular effects, protease detection and quantization in peripheral blood may help 
detect atheromatous disease stages and aid in clinical decision-making (Vivanco et al., 2005). 
Patients with coronary artery stenosis have demonstrated increased serum cathepsin L 
levels than those without lesions detectable by quantitative angiography (Liu et al., 2006a). 
Increased serum cathepsin S has been demonstrated in patients with atherosclerosis and 
diabetes (Liu et al., 2006b) and increased cathepsin D both in plasma and monocytes of ACS 
patients. In our study increased peripheral blood levels of cathepsin B and K and decrease in 
their inhibitor cystatin C at the acute phase of MI were observed (Shalia et al., 2011). 
Moreover plasma concentration of MMP-9; recently identified as a novel predictor of 
cardiovascular mortality in patients with CAD and also marker for plaque destabilization 
and rupture demonstrated strong positive correlation with cathepsin B and negative 
correlation with cystatin C in AMI group (Shalia et al., 2011).  
1.2.3.4 Pregnancy-Associated Plasma Protein-A (PAPP-A) 
It is known as high molecular weight (200kDa) glycoprotein synthesized by the syncytio-
trophoblast and is typically measured during pregnancy for Down syndrome screening. It is 
pro-atherosclerotic molecule family of proteins; a member of the insulin-like growth factor 
(IGF) –dependent IGF binding protein-4 specific metalloproteinase (Bayes-Genis et al., 2000). 
It is thought to be released when neovascularization occurs and thus may be a marker of 
incipient plaque rupture which was later confirmed in studies demonstrating its increased 
expression in unstable plaques and their extracellular matrices (Bayes-Genis et al., 2001) and 
corresponding increased circulating levels in unstable angina and AMI (Bayes-Genis et al., 
2001). Interestingly, it demonstrated increase in risk of cardiovascular death, MI or 
revascularisation even without a raised Troponin (Lund et al., 2003). Evidence for the use of 
this biomarker clinically remains scarce but promising. More studies and standardized 
assays will be needed to improve its clinical utility. 
1.2.4 Components representing oxidative stress 
Oxidative stress in conjunction with inflammation is the one of the important initiators of 
atherosclerosis. However they also play important role in increasing the severity of 
pathogenesis of ACS. 
1.2.4.1 Oxidized LDL (Ox-LDL) 
Ox LDL is involved at very early critical steps of atherosclerosis. Oxidized LDL as well as its 
antibody (ox-LDL Ab) have been documented to be elevated in ACS patients including AMI 
and Unstable Angina and were suggested to be helpful in diagnosis of ACS (Zhou e tal., 
2006). Imazu et al (2008) examined the relationship among plasma levels of OxLDL, 
measured by an enzyme immunoassay using an antibody against OxLDL (FOH1a/DLH3) 
and apolipoprotein B, at the onset of ACS. Plasma levels of OxLDL were significantly higher 
in patients with new-onset type ACS than in those with worsening type ACS (2.98 versus 
1.53 mg/dL, P = 0.002). In conclusion, plasma levels of OxLDL were demonstrated to be 
associated with CHD and significantly higher in patients with new-onset ACS. The findings 
of the study suggested that plasma OxLDL can be a marker of the development of ACS. 
Oxidized low-density lipoprotein (oxLDL)/beta(2)-glycoprotein I (beta2GPI) complexes 
implicated in atherogenesis were also demonstrated to be associated with severe coronary 
artery disease and a 3.5-fold increased risk for adverse outcomes (Greco et al., 2010).  
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1.2.4.2 Lectin-like Oxidized low density lipoprotein receptor-1 (LOX-1) 
LOX-1 is a multi-ligand receptor, whose repertoire of ligands includes oxidized low-density 
lipoprotein, advanced glycation endproducts, platelets, neutrophils, apoptotic/aged cells 
and bacteria. Sustained expression of LOX-1 by critical target cells, including endothelial 
cells, smooth muscle cells and macrophages in proximity to these ligands, sets the stage for 
chronic cellular activation and tissue damage suggesting the interaction of cellular LOX-1 
with its ligands to contribute to the formation and development of atherosclerotic plaques. 
(Navarra et al, 2010). It was demonstrated to be elevated in ACS patients but not correlating 
with troponins or CK suggesting it not to be a marker of cardiac injury (Hayashida 2005). 
Kamezaki (2009) in an another study have shown it to be positively correlating with urinary 
8-isoprostane and negatively correlating with superoxide dismutase in ACS patients 
suggesting that increased serum LOX-1 reflect enhanced oxidative stress in vascular wall.  
1.2.4.3 Lipoprotein-associated Phospholipase A-2 (Lp-PLA-2) 
Lp-PLA2, also known as the platelet activating factor acetylhydrolase, is a monomeric 
enzyme that catalyzes the hydrolysis of the sn-2 ester bond, preferentially when short acyl 
groups are at the sn-2 position, of oxidized phospholipids. The cascade of Lp-PLA2 activity 
may eventually lead to plaque destabilization, increasing the possibility of rupture and 
thrombosis (Hsieh et al., 2000). Confirming the same, circulating levels of sPLA2 were found 
to increase not only in various chronic inflammatory diseases but also independently 
predicted clinical coronary events in patients with unstable angina and documented 
coronary artery disease (Kugiyama et al., 1999, 2000).  
1.2.5 Molecules of inflammation 
Although molecules of inflammation may have its primary role as the indicator of 
endothelial dysfunction and in development of atherosclerotic plaque, its soluble levels have 
been implicated in various studies to be associated with ACS. 
1.2.5.1 Vascular Cell Adhesion Molecule (VCAM-1) 
VCAM-1 is not routinely expressed under physiological conditions. Expression of VCAM-1 
occurs only on activated endothelium and vascular smooth muscle cells in developing 
atherosclerotic lesion (Braun et al., 1999). It was demonstrated to be expressed especially in 
the intimal neovasculature and largely associated with leukocyte accumulation; promoting 
the binding of lymphocytes and monocytes which further move by diapedesis which release 
cytokines and enzymes important for progression of lesion as well as rupture of the plaque 
(O’Brien et al., 1993, 1996). Literature reports correlation of sVCAM-1 with the extent of 
coronary atherosclerosis with elevated levels in AMI (Bossowska et al., 2003, G ϋ ray ϋ, 
Erbay et al., 2004). Consistent with this finding we have observed highest levels with AMI 
patients and unstable angina in decreasing order as compared to controls (Mashru et al., 
2010). In our study age matched analysis also demonstrated younger age group (<=40 years) 
of patients with AMI with highest sVCAM-1 as compared to age matched controls and in 
unstable angina it was more associated with females than male patients. Above observations 
suggest VCAM-1 to be also as an indicator towards ACS in patients with low-risk profile for 
cardiovascular risk factors such as age and gender. 
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1.2.5.2 Platelet Endothelial Cell Adhesion Molecule (PECAM-1) 
PECAM-1 of the immunoglobulin superfamily is with wide variety of functions such as 
platelet activation, inflammation, cell survival, in the immune response and in 
transendothelial migration of monocytes (TEM) (Muller et al., 1993). It has also been 
demonstrated to have role in plaque formation and thrombosis (Newman et al., 1990, 
Mahooti et al., 2000). In our study (Mashru et al., 2010) there was significant increase in 
sPECAM-1 in AMI patients at acute event consistent with the finding of Serebruany et al 
(1999b) and Soeki et al (2003).  
1.2.5.3 Monocyte Chemoattractant Protein-1 (MCP-1) 
MCP-1 is a chemokine responsible for the recruitment of monocytes to sites of inflammation 
that appears to play a critical role in the promotion of plaque instability (Szmitko et al., 
2003). In case control studies, plasma MCP-1 concentrations have been shown to be 
associated with restenosis after coronary angioplasty (Cipollone et al., 2001). However, in a 
prospective study on a large cohort of ACS patients, the distribution of MCP-1 values in the 
healthy subjects and the study population overlapped considerably. However, subsequent 
studies have shown that MCP-1 plasma concentration is associated with different 
cardiovascular risk factors, and a greater risk of developing a cardiovascular event in the 
future (de Lemos et al., 2003, Deo et al., 2004). 
1.2.5.4 Cystatin C 
This biomarker is a low-molecular-weight basic protein (13 kDa) that is freely filtered and 
metabolized after tubular reabsorption. It seems that it is less influenced by age, gender, and 
muscle mass than serum creatinine. There is a U.S. Food and Drug Administration-cleared 
assay that is analytically robust. Some studies suggest that it is useful for prognostication in 
heart failure (Sarnak et al., 2005, Shlipak et al., 2005), and ACS (Jernberg et al., 2004). This 
would make sense as it is well accepted that renal function is a critical determinant of 
prognosis. In our study cystatin C levels did not deviate much from the controls 
maintaining its normal levels with normal kidney functioning and demonstrated negative 
correlation with MMP-9 in AMI group (Shalia et al., 2011). 
1.2.5.5 Interleukin 6 (IL-6) 
As the prototypical acute phase reactants, interleukin-6 (IL-6) has been the focus of 
investigations for the diagnosis of ACS. The Fragmin and Fast Revascularisation During 
Instability in Coronary Artery disease II trial (FRISC) study group showed that the 
circulating level of IL-6 is a strong independent marker of increased mortality among 
patients with unstable angina and is useful in directing subsequent care. However, the best 
timing for measurement of IL-6 for diagnosis and risk stratification of ACS remains 
uncertain (Lindmark et al., 2001). Alwi et al., (2008) concluded that the IL-6 level in ACS 
were higher than those in CHD. The IL-6 level 4.43 pg/mL could differentiate the acute 
condition (ACS) and stable condition (non-ACS) with sensitivity of 89.95% and specificity of 
77.42%, and ROC of 0.87.  
A study by Kavsak et al (2007) demonstrated that IL-6, MCP-1, and a known biomarker, NT-
proBNP were independent predictors of long-term risk of death or HF, highlighting the 
importance of identifying leukocyte activation and recruitment in ACS patients. 
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1.2.5.6 IL-10 
IL-10 is an important anti-inflammatory molecule with so far contradictory findings in ACS 
patients. On one hand it was shown to demonstrate more favorable prognosis in patients 
with ACS (Heeschen et al., 2003) while on the other hand it reflected a proinflammatory 
state in patients with ACS which suggested that IL-10 is as effective biomarker for the risk 
prediction of future cardiovascular events as other markers of systemic inflammation 
(Mälarstig et al., 2008). Extensive study may be required to establish its role in the 
pathogenesis of ACS and its utility as biomarker. 
1.2.5.7 IL-18 
It is a member of the IL-1 cytokine family, originally identified in macrophages and Kupffer 
cells as factor able to induce IFN- production by T cells which itself is a central 
proatherogenic factor. Both increased serum levels of IL-18 and reduced concentrations of 
IL-10 have been shown to have prognostic significance in ACS. Chalikias, et al (2005) sought 
to assess whether the ratio of serum IL-18/IL-10 levels has higher positive predictive value 
than the individual measurement of IL-10 and IL-18 in patients admitted to hospital with 
ACS. Their findings demonstrated that significantly higher odd ratios were found for IL-
18/IL-10 ratio (1.74 95% CI 1.09-2.78) compared to individual IL-18 (1.46 95% CI 0.93-2.27) 
and 1/IL-10 (1.63 95% CI 1.04-2.56) measurements. Recently Hartford et al (2010) 
demonstrated that IL-18 levels were significantly related to all-cause mortality, even after 
adjustment for clinical confounders (hazard ratio [HR], 1.19; 95% confidence interval, 1.07 to 
1.33; P=0.002). Long-term, cardiovascular mortality was univariately related to IL-18, and 
the adjusted relation between noncardiovascular mortality and IL-18 was highly significant 
(HR, 1.36; 95% confidence interval, 1.11 to 1.67; P=0.003). IL-18 independently predicted 
congestive heart failure, MI, and cardiovascular death/congestive heart failure/MI in both 
the short and long term. Measurements from day 1 of ACS and 3 months after ACS had a 
similar power to predict late outcome. 
The data from the PRIME Study, a prospective cohort of 9758 asymptomatic middle-aged 
men recruited in Northern Ireland and France between 1991 and 1993.demonstrated that 
higher circulating levels of Hs-CRP, intercellular CAM-1 (ICAM-1), IL6 and IL18 to be 
equally predictive of stable angina and ACS (all P-values of OR comparison >0.05) (Empana 
et al., 2008). 
1.2.5.8 High-sensitivity C-Reactive Protein (HsCRP) 
It is thought that one of the driving forces causing atheromatous plaques to rupture or 
erode, causing a cascade of events leading to coronary artery occlusion, is inflammation in 
the plaques (Ridker, 2003, Shishehbor et al., 2003). CRP itself mediates atherothrombosis 
which is supported by a fairly large body of evidence (Pasceri et al., 2000, Nakajima et al., 
2002, Nakagomi et al., 2000, Verma et al., 2002, Devaraj et al., 2003). The benefits of HsCRP 
testing in a primary setting to screen for ischaemic heart disease is very clear, People are risk 
stratified based on amount of CRP in blood. There are three groups; less than 1mg/l of CRP 
is low risk group, between 1 – 3mg/l is classified as the moderate risk group and more than 
3mg/l is the high risk group (AHA/CDC, 2003). However, its use post-ACS or -MI is less 
clear. CRP is elevated post-acute coronary syndrome almost exclusively in the setting of 
myocardial necrosis indicating the level of myocardial inflammation. In a study carried out 
by us, we observed a three fold increase in the total HsCRP levels in MI patients at 
presentation; as compared to controls (Shalia et al., 2011). 
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Elevated peak CRP in the early phase of MI is related to early mechanical complications, 
including cardiac rupture, ventricular aneurysm and thrombus formation (Anzai et al., 
1997). CRP levels post-MI peak at two to four days, then take 8 to 12 weeks to subside to 
baseline levels. One of the difficulties with CRP is that it is non-specific and also is elevated 
in the presence of other inflammatory conditions (rheumatoid arthritis, malignancy, 
vasculitis etc.). A new assay for Human Pentraxin 3 is now available. Human Pentraxin 3 is 
an isoform which is secreted exclusively in vascular endothelium and therefore may be 
more specific to the vascular plaque inflammatory activity (Matsui et al., 2010). It remains to 
be seen if this biomarker can provide incremental information. 
2. Conclusion 
Thus, non invasive indicators of separate pathobiologically diverse contributors to the 
progression of ACS, such as molecules of inflammation, components of plaque rupture and 
thrombosis, could add complementary information in variety of clinical settings. The role of 
these components in multi-marker testing, in identifying the high-risk individuals, the 
pathophysiologic stage of the disease and tailoring therapy needs to be established. The 
future of ACS management would probably shift from single to multi-marker testing 
leading to better characterization of each individual case by using a combination of both 
established and new markers for risk assessment and clinical decision making that will 
substantially improve the outcomes in patients with ACS. 
Growing hand in hand with our contemporary fascination are the promises of personalized 
medicine, the discovery of novel biomarkers in cardiovascular diseases which has been 
embraced as a major objective of government, private and industry supported research 
initiatives. More than a decade of advances in our understanding of the complex 
mechanisms underlying the initiation, progression of atherothrombosis and its 
complications has stimulated efforts to identify and characterize new markers associated 
with this processes. In addition newer screening based discovery techniques such as 
metaloblomics and proteomics have revealed large numbers of candidate metabolites and 
proteins associated with this disease for which the function or role in pathophysiology has 
yet to be explained. The clinical application of cardiac biomarkers in ACS is no longer 
limited to establishing or refuting the diagnosis of myocardial necrosis. Cardiac biomarkers 
provide a convenient and non invasive means to gain insights into the underlying causes 
and consequences of ACS that mediate the risk of recurrent events and may be targets for 
specific therapeutic interventions.  
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